1Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer : a surgical perspective. Eur J Cancer, 2002,38 ( 17 ) :2214-2221.
2Hoff PM,Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer,2000,88(9):2054-2060.
3Dixon JM, Love CD, Bellamy CO, et al. Izetrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat,2001,66 ( 3 ) : 191-199.
4Eiermann W, Paepke S, Appfelstaedt J,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doable-blind multicen|er study. Ann Oncol, 2001,12 ( 11 ) : 1527-1532.
5Ellis MJ, Coop A, Singh B,et. al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase Ⅲ randomized trial. J Clin Oncol,2001,19(18) :3808-3816.
6Milla Santos A, Milla L, Cairo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone- dependent, locally- advanced breast cancer. Anticancer Res,2004,24 (2C) : 1315-1318.
7Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res,2000,6(6) :2229-2235.
8Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control,2002,9(2 Suppl) :9-15.
9Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer, 2004,11(2) :129-133.
10Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant(CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol, 2003,86(3-5 ) :443-447.
